Killer antibodies against AML
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia. Working with patients who are in remission from AML, we discovered antibodies that bind specifically to AML cells. We suspect that these antibodies have general utility in treating other patients with AML. The target of these antibodies was unanticipated: the U5 snRNP200 protein complex, normally expressed in the cell cytoplasm and nucleus but expressed on the outer surface of AML cells. Moreover, we found that U5 specific antibodies are ‘killer antibodies’: they kill AML blasts in vitro and (in a mouse model) in vivo. We are now advancing these antibodies through early development with the goal of initiating human clinical trials in the near future. (see also infographic (dutch) at: https://www.amc.nl/web/AMC-website/AMCFoundation/Uitgelicht/Hematologie.htm)
Presenter: Dr Mette Hazenberg
Affiliation: Academic Medical Center Amsterdam, the Netherlands
Topic: ACUTE MYELOID LEUKEMIA (AML) PATIENTS CURED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION GENERATE TUMOR-SPECIFIC CYTOTOXIC ANTIBODIES THAT KILL AML BLASTS
Abstract S124 will be presented by Mette Hazenberg on Friday, June 10, 11:45 - 12:00 in Hall C13.
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments. The latest data on research and developments will be presented. The topics range from stem cell physiology and development, to leukemia, lymphoma, myeloma - diagnosis and treatment; red blood cells -, white blood cells- and platelet disorders; thrombosis and bleeding disorders.
EHA Executive Office
Ineke van der Beek, Jon Tarifa
Mobile: +31(0)6 2011 1055